Skip to main content
Clinical Trials/NCT00482690
NCT00482690TerminatedNot Applicable

Analysis of Aldehyde Biomarkers of Exposure and Host Response

University of Nebraska1 site in 1 country35 target enrollmentStarted: August 23, 2005Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
35
Locations
1
Primary Endpoint
Aldehyde Biomarkers

Study Overview

Brief Summary

Analysis of aldeyde biomarkers of exposure and host response The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. This will be accomplished by measuring selected markers in EBC believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

Detailed Description

Twenty subjects will be accrued in three groups based on smoking habit: 10-20, 20-30 and >30 cigarettes/day. Eligibility criteria include male and female cigarette smokers ≥19 years of age, who are able to give informed consent, able to exhale into Eco Screen instrument for 15-20 minutes. All must be willing to make a serious quit attempt and be willing to use nicotine replacement therapy.

Subjects will be excluded if any of the following are present: regular use of anti-inflammatory medication; presence of any inflammatory disease of the respiratory tract including moderate or worse COPD (FEV1 < 80% predicted and FEV1/FVC ratio < 0.7). Subjects with normal lung function who meet criteria for diagnosis of chronic bronchitis will be excluded. Subjects with stable medical conditions, excluding inflammatory lung disease, will be permitted to participate, providing anti-inflammatory therapies are not used regularly and providing there has been no change in their clinical status in the two months prior to beginning the study.

Upon entering into the study, subjects will establish a quit date and will be treated with nicotine replacement therapy (NRT) products based on individual preference and will receive smoking cessation counseling. They will then be seen at 12 visits over the course of 25 weeks.

Evaluations will include vital signs, interval smoking history, food frequency questionnaire, exhaled carbon monoxide, blood drawn for chemistry and CBC, peripheral blood harvested and serum aliquoted and saved for future biochemical analysis, urine sample for isoprostane, pregnancy test for females, and exhaled breath condensate. Some visits may also include spirometry with and with out bronchodilators, 24 hour urine collections for NNAL and NNAL-glc quantification, health status assessed using St. George's Respiratory Questionnaire, the Functional Assessment of Chronic Illness Therapy - Fatigue, the Leicester Cough Questionnaire, the Clinical COPD Questionnaire and smoking related symptoms assessed using the Breathlessness, Cough, and Sputum Scale.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Smokers of at least 5 pack years;
  • Stable smoking habit for 3 months;
  • Willing to make a serious quit attempt;
  • Able to use nicotine replacement therapy

Exclusion Criteria

  • Regular use of anti-inflammatory medication
  • Inflammatory lung disease
  • Unstable medical condition

Arms & Interventions

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

Intervention: nicotine polacrilex (Drug)

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

Intervention: nicotine transdermal system (Drug)

Nicotine replacement therapy (NRT)

Experimental

open label NRT self comparator design

Intervention: nicotine inhaler (Drug)

Outcomes

Primary Outcomes

Aldehyde Biomarkers

Time Frame: Study was terminated at an interim analysis for futility

Aledhydes were assessed in exhaled breath condensate by mass spec and chemical assay.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Analysis of Aldehyde Biomarkers of... | Clinical Trial